Recent preclinical and clinical testing of hypocrellin-based photosensitizer SL052 for use in photodynamic therapy (PDT) of cancer has shown encouraging results. Further optimization of …

2020年6月1日 · Poly (lactic-co-glycolic acid) (PLGA) nanoparticles of hypocrellin photosensitizer SL052 enhanced the antitumor efficacy of photodynamic therapy. Korbelik and his associates …

A diaminophenyl derivative of hypocrellin B (SL052) has been developed as a photosensitizer for use in photodynamic therapy (PDT) of solid tumors. Testing SL052-PDT on mouse carcinoma …

2011年11月9日 · Recent preclinical and clinical testing of hypocrellin-based photosensitizer SL052 for use in photodynamic therapy (PDT) of cancer has shown encouraging results. …

SL-052 is a hypocrellin-based photosensitizer that has recently shown promising results in clinical and preclinical testing for cancer photodynamic therapy (PDT). SL-052 is encapsulated in …

In this article, we present a water-soluble nanocarrier to load the SDT/PDT sensitizer SL052 with improved pharmacokinetics and therapeutic efficacy. Materials & methods: Nanoclusters of …

A water-soluble nanocarrier to load the SDT/PDT sensitizer SL052 with improved pharmacokinetics and therapeutic efficacy greatly improved the physicochemical properties of …

In this article, we present a water-soluble nanocarrier to load the SDT/PDT sensitizer SL052 with improved pharmacokinetics and therapeutic efficacy. Materials & methods: Nanoclusters of …

2011年11月9日 · Recent preclinical and clinical testing of hypocrellin‐based photosensitizer SL052 for use in photodynamic therapy (PDT) of cancer has shown encouraging results. …

2009年3月4日 · The results indicate the potential of SL052 PDT for use in combination with cancer vaccines to generate a superior immune response compared with vaccines alone. The …